Caffeic Acid.

Chlorogenic acid hydrolyses in the gut and by colonic esterases to release free caffeic acid. The two are precursor and product rather than independent compounds.

Catechol-O-methyltransferase converts caffeic acid into ferulic acid in the enterocyte and liver, so circulating ferulate partly comes from ingested caffeate. Dosing both saturates the same methylation step.

Rosmarinic acid is caffeic acid esterified to a dihydroxyphenyllactic unit and releases free caffeic acid on hydrolysis. Formulas carrying both are delivering overlapping chemistry.

When caffeic acid quenches a radical it becomes a phenoxyl radical, which ascorbate can reduce back to the parent catechol. That recycling is why phenolic acids and ascorbate are formulated together in antioxidant blends.

Tocopherol handles chain-breaking inside the lipid membrane while caffeic acid works at the aqueous interface, and the two hand radicals along the same regeneration chain with ascorbate. Their phases are complementary rather than redundant.

Both are catechol-bearing polyphenols cleared by COMT methylation and sulfation, so they compete for the same conjugating capacity. Co-dosing tends to raise the unconjugated fraction of each.

The catechol group of caffeic acid binds ferric iron tightly and holds it in a form the gut cannot take up. Polyphenol-rich doses taken with a meal lower non-heme iron uptake from that meal.

Caffeic acid is largely lost to glucuronidation and sulfation in the gut wall before it reaches circulation. Piperine slows both conjugating enzymes, raising the free phenolic fraction that gets through.

Caffeic acid phenethyl ester is one of the defining constituents of poplar-type propolis, so a propolis extract already delivers caffeic acid chemistry alongside flavonoids. The two are compositionally linked rather than independently combined. Anything claimed for the pairing rests on the extract literature, most of it preclinical.

Rutin is a quercetin glycoside that donates hydrogen atoms from its catechol B ring, the same structural motif that makes caffeic acid a chain-breaking antioxidant. In mixed polyphenol systems the two regenerate each other's radicals, which is measurable in vitro. Read it as chemistry rather than as a clinical outcome.

Proanthocyanidins and caffeic acid both carry ortho-dihydroxy phenolic groups and both scavenge peroxyl radicals. Mixed polyphenol preparations behave differently from single compounds because the radicals formed are regenerated within the mixture. The interaction is well characterised in chemical assays and not established as a human outcome.

Caffeic acid and catechins are both handled by intestinal and hepatic catechol-O-methyltransferase, sulfotransferases and UGTs. When taken together in quantity they compete for that conjugating capacity, which can raise the unconjugated fraction of either. The competition is a pharmacokinetic fact; whether it changes any endpoint has not been measured in people.

Dihydrolipoic acid regenerates oxidised forms of several small-molecule antioxidants, keeping the network in its reduced state. Caffeic acid sits in that network as a phenolic hydrogen donor. The relationship is redox chemistry and applies to markers of oxidative status rather than to any clinical endpoint.

Oxidised caffeic acid forms an ortho-quinone that is conjugated by glutathione, which both detoxifies the quinone and consumes reduced glutathione. At ordinary dietary exposures this is a routine handling step. It explains why polyphenol dosing and glutathione status move together in cell systems.

N-acetylcysteine supplies cysteine, the rate-limiting substrate for glutathione synthesis, and glutathione is what conjugates phenolic quinones formed when caffeic acid is oxidised. The pairing supports the cell's own handling capacity rather than adding antioxidant activity directly. This is established biochemistry, not a tested combination.

Polyphenols including caffeic acid can chelate divalent cations, and intracellular zinc availability shapes the reactive oxygen species response in cultured microglia. The work is in vitro and mechanistic. It flags an interaction to watch in formulation, not an effect in people.

Caffeic acid reaching the colon is metabolised by gut bacteria to smaller phenolic acids, and in challenged piglets caffeic acid supplementation shifted microbiota composition. Live cultures alter the same community that performs that conversion. The evidence is animal and compositional, so treatment of it as a human outcome would overstate it.

Chicory is a dietary source of caffeic acid derivatives and inulin at the same time. Fermentable fibre supports the colonic bacteria that hydrolyse and reduce phenolic acids to absorbable metabolites. The pairing is mechanistically coherent and the supporting work is preclinical and observational.

Maritime pine bark extract contains caffeic acid among its phenolic constituents, so the two overlap compositionally. A human supplementation study reports on the extract as a whole, not on caffeic acid isolated from it. Attributing the extract's results to caffeic acid alone would go beyond what the source shows.

Carotenoids quench singlet oxygen in the lipid phase while phenolic acids act at the aqueous interface, so the two cover different compartments. In model lipid systems phenolics spare carotenoid loss. This is measured chemistry in models rather than a clinical finding.

Astaxanthin spans the lipid bilayer with polar ends exposed, while caffeic acid stays near the membrane surface. Together they cover both faces of the membrane in oxidation models. The rationale is physicochemical and has not been tested as a combination in people.

Both compounds are heavily glucuronidated and sulfated during first pass, and both are commonly co-formulated in polyphenol blends. Competition for UGT and SULT capacity can raise circulating parent compound of either. This is a pharmacokinetic interaction, and it cuts in the direction of exposure, not efficacy.